menu
    • menu
    [{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Russian Direct Investment Fund \/ AstraZeneca"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Russian Direct Investment Fund \/ AstraZeneca"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Russian Direct Investment Fund

                            Russia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Russian Direct Investment Fund

                            Russia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ChAdOx1 nCoV-19,rAd26-S

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Approval Of Mixing and Matching of COVID Booster Shots By FDA is yet Another Confirmation of Efficacy of Vacci...

                            Details : Sputnik V's efficacy against infection with the Delta variant is 83% and 94% against hospitalization. To date Sputnik V has been registered in 70 countries in various parts of the world with total population of over 4 billion people.

                            Product Name : AZD1222

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 21, 2021

                            Lead Product(s) : ChAdOx1 nCoV-19,rAd26-S

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Russian Direct Investment Fund

                            Russia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Russian Direct Investment Fund

                            Russia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RDIF and ChemRar Launch Final Stage of Favipiravir Clinical Trial

                            Details : RDIF and ChemRar have applied to the Russian Ministry of Health for the accelerated registration of Favipiravir in accordance with the Russian Government's Decree.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 22, 2020

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth